177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration-Resistant Prostate Cancer (CRPC)
- Colorectal Cancer
- NSCLC (Non-small Cell Lung Cancer)
- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- TNBC, Triple Negative Breast Cancer
- Small Cell Lung Cancer (SCLC )
- Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)
- Esophageal Squamous Cell Carcinoma (ESCC)
- Sarcoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Radiopharm Theranostics, Ltd
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Dothan Hematology & Oncology · Dothan, AL
Michigan · 1
- BAMF Health · Grand Rapids, MI
Nebraska · 2
- Nebraska Cancer Specialists · Omaha, NE
- XCancer · Omaha, NE
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.